PubMed Health⌕ Search

Biomedical subjects

R Pardon

Publications and source records attributed to R Pardon.

17 recordsLinked to original sources

Bronchoscopy in the diagnosis and therapy of chest injuries.

Owing to its technical possibilities, bronchoscopy has also come into frequent use in the treatment of trauma patients, not only for diagnostic but also for therapeutic purposes. It has become a mandatory procedure in the treatment of chest injuries. Following discussion of its history, possibilities and scope, the authors present the results of treatment over the last two years at the University Hospital of Traumatology Zagreb, Croatia. There were 407 bronchoscopies performed in 157 trauma patients (on the average, 2.59 bronchoscopies per patient). According to indications for bronchoscopy, patients were classified into four groups: (a) patients with atelectasis (N = 51), with a total of 68 bronchoscopic procedures (1.33 per patient; (b) patients who developed infiltrates (N = 48) with 162 bronchoscopies (3.37 per patient); (c) patients with excessive secretions (N = 42) with 153 bronchoscopies (3.64 per patient); and (d) patients who developed respiratory insufficiency in the course of treatment (N = 16) with 24 bronchoscopic procedures (1.5 per patient). The best results were achieved in the atelectasis patients--in 74.47% of them there was no need of additional bronchoscopies, whereas in the group with excessive secretions or infiltrates bronchoscopy had to be repeated several times. It may be concluded that today, bronchoscopy is a routine diagnostic and therapeutic method in the treatment of chest injuries.

Bronchoscopy↗

Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study.

104 patients with chronic bronchitis were treated under randomized double-blind conditions with either Broncho-Vaxom (BV) or a placebo over a period of 6 consecutive months. The beneficial effect of BV was manifested by a statistically significant reduction in the duration of acute episodes and of fever (p less than 0.001) with respect to the placebo group. The consumption of antibiotics dropped significantly in the BV group (p less than 0.05) but not in the placebo group. The serum IgA levels increased in the BV group and the difference with the placebo group was statistically significant (p less than 0.05) from the 3rd month onwards. In the patients with bronchitic exacerbations during the trial, T-lymphocyte counts increased steadily under BV therapy until 3 months after the exacerbation (p less than 0.05), but not under the placebo. BV was generally well tolerated with the exception of 1 patient who reported nausea and upper abdominal pain. In their assessment of the overall therapeutic effect, the physician judged BV to be significantly superior (p less than 0.001) to the placebo as regards both the curative and prophylactic efficacy.

Adjuvants, Immunologic↗